ANI
31 Jan 2023, 07:55 GMT+10
Pennsylvania [US], January 31 (ANI): The possibility of treating Alzheimer's and other neurodegenerative illnesses by introducing wholesome, fresh immune cells into the brain has grown significantly. Researchers from the Universities of California, Irvine and Pennsylvania have safely overcome the brain's resistance to them, overcoming a significant obstacle.
Their discovery of a class of brain cells known as microglia opens up a world of therapeutic and preventive options for neurodegenerative diseases. In the Journal of Experimental Medicine, the team's paper is published.
When microglia are healthy, they serve as the central nervous system's resident front-line disease warriors. "However, there is overwhelming evidence that they can become dysfunctional in many neurological conditions," said Mathew Blurton-Jones, UCI professor of neurobiologybehaviour and study co-lead author, adding, "Until recently, scientists have mainly been looking at the mechanisms that drive microglial dysfunction and trying to find drugs to change their activity. But with this study, we've found a way to harness microglia themselves to treat those diseases potentially."Frederick 'Chris' Bennett, assistant professor of psychiatry at Penn and co-lead author, added: "There is an obstacle because once our own microglia develop in the location where they are supposed to be in our brains, they don't give up that space. They block the ability to deliver new cells that would take their place. If you want to insert donor microglia, you have to deplete the host microglia to open up the room."Bennett and his laboratory partnered with Blurton-Jones and his lab on the project.
Microglia depend on signalling by a protein on their surface called CSF1R for their survival. The FDA-approved cancer drug pexidartinib has been found to block that signalling, killing them. This process would seem to offer a way to clear space in the brain to insert healthy donor microglia. However, there is a dilemma - unless the pexidartinib is stopped before the donor microglia are added, it will eliminate them, too. But once the drug is terminated, the host microglia regenerate too fast to effectively put in the donor cells.
This quandary has challenged efforts to treat people with certain rare and severe neurologic conditions. One is Krabbe disease, in which the body's cells can't digest certain fats that are highly abundant in the brain. Currently, clinicians use bone marrow transplantation and chemotherapy to try to introduce new immune cells similar to microglia into the brain. But this approach can be toxic and must be carried out before Krabbe symptoms manifest.
"Our team believed that if we could overcome the brain's resistance to accepting new microglia, we could successfully transplant them into patients using a safer, more effective process in order to target a great number of diseases," said co-first author Sonia Lombroso, a Penn PhD student and member of the Bennett Lab, adding, "We decided to investigate whether we could make the donor microglia resistant to the drug that eliminates their host counterparts."The researchers used CRISPR gene-editing technology to create one amino acid mutation, known as G795A, which they introduced into donor microglia produced from human stem cells or a mouse microglial cell line. Then they injected the donor microglia into humanized rodent models while administering pexidartinib, with exciting results.
"We discovered that this one small mutation caused the donor microglia to resist the drug and thrive, while the host microglia continued to die off," said co-first author Jean-Paul Chadarevian, a UCI PhD student who is a member of the Blurton-Jones Lab, adding, "This finding could lead to many options for developing new microglial-based treatments. Pexidartinib is already approved for clinical use and appears to be relatively well tolerated by patients."Approaches could range from fighting disease by replacing dysfunctional microglia with healthy ones to designing microglia that can recognize imminent threats and strike against them with therapeutic proteins before they cause harm.
The UCI-Penn team believes treatments based on this kind of microglial method could be developed within a decade. Their subsequent investigations include studying in rodent models how to use the approach to attack the brain plaques associated with Alzheimer's and to counter Krabbe and other similar diseases. (ANI)
Get a daily dose of Africa Leader news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Africa Leader.
More InformationIn Warsaw last February, President Joe Biden condemned the lawless Russian invasion of Ukraine: "The idea that over 100,000 forces ...
TOKYO, Japan: Fears over intensifying Chinese military activity directed towards Taiwan could escalate into war have prompted Japan, the United ...
TEGUCIGALPA, Honduras: After Honduran President Xiomara Castro severed ties with Taiwan in favor of China to gain more investment and ...
NEW YORK, New York - A Manhattan grand jury has indicted Former U.S. President Donald Trump for his role in ...
MEMPHIS, Tennessee: Tennessee authorities are slowly releasing information about a weekend car crash on a freeway that killed six young ...
JAKARTA, Indonesia: Officials from Indonesia's Aceh province said that more than 180 Rohingya Muslims landed this week by boat, in ...
NEW YORK, New York - U.S. stocks finished the third quarter with a bang on Friday. Despite a volatile start, ...
CUPERTINO, California: In a move aimed at disrupting the fintech sector dominated by Affirm Holdings and Sweden's Klarna, this week ...
BURBANK, California: Walt Disney has begun its planned lay off of 7,000 staff, which was announced earlier this year.A letter ...
NEW YORK CITY, New York: A study published this week reported that China spent $240 billion between 2008 and 2021 ...
NEW YORK, New York - U.S. stocks posted a decent rally on Thursday with all the major indices making good ...
FREMONT, California: Neuralink, Elon Musk's brain implant company, has approached the Barrow Neurological Institute, one of the largest US neurosurgery ...